Loading...
Market
Story
Pfizer's RSV Vaccine Shows Strong Results in Immunocompromised Adults
Aug 12, 2024, 11:00 AM
Pfizer announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has demonstrated a strong immune response in a late-stage study involving immunocompromised adults aged 18 and older. The study showed that a single dose of the vaccine produced robust antibodies against RSV-A and RSV-B, indicating potential benefits for adults at risk of severe RSV-related illness. The top-line results highlight the vaccine's efficacy in generating an immune response in this vulnerable population.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%